Search Result

Results for "

diabetic neuroinflammation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (2) Amyloid-β (1) Apoptosis (3) Autophagy (1) Bacterial (1) Bcl-2 Family (1) Beclin1 (1) Btk (1) Cannabinoid Receptor (1) Caspase (1) Cholinesterase (ChE) (1) COX (1) DNA/RNA Synthesis (1) FAK (1) FOXO (1) Fungal (1) GLUT (1) Glycosidase (1) Interleukin Related (2) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) mTOR (2) MyD88 (1) NF-κB (1) Notch (1) p38 MAPK (1) Phosphatase (1) PPAR (1) Reactive Oxygen Species (ROS) (2) Sirtuin (1) SOD (1) STAT (1) Target Protein Ligand-Linker Conjugates (1) Tau Protein (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Wnt (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (5)

By Targets:

Akt (1)

AMPK (2)

Amyloid-β (1)

Apoptosis (3)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (1)

Beclin1 (1)

Btk (1)

Cannabinoid Receptor (1)

Caspase (1)

Cholinesterase (ChE) (1)

COX (1)

DNA/RNA Synthesis (1)

FAK (1)

FOXO (1)

Fungal (1)

GLUT (1)

Glycosidase (1)

Interleukin Related (2)

Keap1-Nrf2 (1)

Lactate Dehydrogenase (1)

mTOR (2)

MyD88 (1)

NF-κB (1)

Notch (1)

p38 MAPK (1)

Phosphatase (1)

PPAR (1)

Reactive Oxygen Species (ROS) (2)

Sirtuin (1)

SOD (1)

STAT (1)

Target Protein Ligand-Linker Conjugates (1)

Tau Protein (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

Wnt (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (3)

Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-43521

Ibrutinib-MPEA	Target Protein Ligand-Linker Conjugates Btk STAT	Inflammation/Immunology Cancer
Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .

HY-N2896

Arjunolic acid	Reactive Oxygen Species (ROS) Apoptosis Fungal Bacterial NF-κB SOD AMPK mTOR Notch Toll-like Receptor (TLR) Wnt MyD88 Sirtuin	Infection Neurological Disease Inflammation/Immunology Cancer
Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction .

HY-N1479

Polygalic acid	Cholinesterase (ChE) DNA/RNA Synthesis	Infection Neurological Disease Metabolic Disease
Polygalic acid is a polyphenolic acid with neuroprotective effects, and also an inhibitor of African swine fever virus polymerase (AsfvPolX), with an IC₅₀ value of 5.05 μM. Polygalic acid alleviates neuroinflammation by regulating cholinergic activity, and its fecal level decreases in diseased mice. Polygalic acid can be used in research related to painful diabetic peripheral neuropathy complicated with cognitive impairment and African swine fever .

HY-121811

Pongamol Lanceolatin C	Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy	Neurological Disease Inflammation/Immunology Cancer
Pongamol (Lanceolatin C) is an orally active flavonoid with an IC₅₀ of 75 μM and a K_i of 58 μM against PTPase-1B, and an IC₅₀ of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .

HY-14728

Aleglitazar R1439; RO0728804	PPAR	Metabolic Disease
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC₅₀s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .

HY-145604

Vicasinabin RG7774	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC₅₀ values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization .

HY-182469

FuBIG	Lactate Dehydrogenase AMPK FOXO Interleukin Related Reactive Oxygen Species (ROS) TNF Receptor Bcl-2 Family Caspase Apoptosis	Neurological Disease
FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2896

Arjunolic acid	Triterpenes Structural Classification Classification of Application Fields Juglandaceae Terpenoids Cyclocarya paliurus (Batal.) Iljinsk. Plants Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Apoptosis Fungal Bacterial NF-κB SOD AMPK mTOR Notch Toll-like Receptor (TLR) Wnt MyD88 Sirtuin
Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction .

HY-N1479

Polygalic acid	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polygalaceae Other Diseases Plants Polygala tenuifolia Willd. Disease Research Fields Source Classification	Cholinesterase (ChE) DNA/RNA Synthesis
Polygalic acid is a polyphenolic acid with neuroprotective effects, and also an inhibitor of African swine fever virus polymerase (AsfvPolX), with an IC₅₀ value of 5.05 μM. Polygalic acid alleviates neuroinflammation by regulating cholinergic activity, and its fecal level decreases in diseased mice. Polygalic acid can be used in research related to painful diabetic peripheral neuropathy complicated with cognitive impairment and African swine fever .

HY-121811

Pongamol Lanceolatin C	Structural Classification Pongamia pinnata (L.) Pierre Leguminosae Ketones, Aldehydes, Acids Derris trifoliata Lour. Plants Source Classification	Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy
Pongamol (Lanceolatin C) is an orally active flavonoid with an IC₅₀ of 75 μM and a K_i of 58 μM against PTPase-1B, and an IC₅₀ of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

diabetic neuroinflammation

Inhibitors & Agonists

NaturalProducts

Natural
Products